版本:
中国

UPDATE 3-Germany's Fresenius in talks to buy generic drugmaker Akorn

(Adds Akorn's statement)

April 7 German healthcare group Fresenius SE & Co KGaA said on Friday that it was in talks with the generic drugmaker Akorn Inc for a potential takeover.

Shares of Akorn, which has a market value of about $3.7 billion, were up 10 percent at $32.60 in aftermarket trading.

There can be no assurance any transaction will result from these discussions, Fresenius said in a statement.

Akorn confirmed the talks with Fresenius, whose businesses range from kidney dialysis and tube feeding equipment to running hospitals.

Fresenius's chief executive, Stephan Sturm, had signaled that acquisitions would be a hallmark of his leadership after he took over the top job in July.

In September, the company made its biggest deal ever with the acquisition of Spain's private hospital chain Quironsalud for 5.8 billion euros ($6.14 billion), including assumed debt.

Bloomberg had reported earlier in the day that Fresenius was weighing a bid for the company. ($1 = 0.9441 euros) (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D'Silva)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐